Conéctate
E-mail
Contraseña
Mostrar la contraseña
Recuerde
¿Olvidó su contraseña?
Inscríbase gratis
Regístrate
Regístrate
Configuraciones
Configuraciones
Cotizaciones dinámicas 
OFFON

EXAGEN INC.

(XGN)
ResumenCotizacionesGráficosNoticiasRatingsAgendaEmpresaFinanzasConsensoRevisionesDerivados 
ResumenTodasRecomendaciones analistasOtros idiomasComunicadosPubls. oficialesNoticias del sector
Noticias en otros idiomas sobre EXAGEN INC.
17/11Exagen Inc. to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conferen..
17/11Exagen Inc. to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conferen..
10/11EXAGEN INC. Management's Discussion and Analysis of Financial Condition and Results ..
10/11Exagen Inc. Reports Third Quarter 2021 Results - Form 8-K
10/11Earnings Flash (XGN) EXAGEN Reports Q3 Revenue $12.3M, vs. Street Est of $12.1M
10/11Earnings Flash (XGN) EXAGEN Posts Q3 Loss $-0.42, vs. Street Est of $-0.47
10/11EXAGEN INC. : Results of Operations and Financial Condition (form 8-K)
10/11Exagen Inc. Reports Third Quarter 2021 Results
10/11Exagen Inc. Provides Revenue Guidance the Full Year 2021
04/11Exagen Inc. to Participate in the 2021 Canaccord Genuity Virtual MedTech, Diagnostics a..
27/10Exagen to Announce Third Quarter 2021 Financial Results on November 10, 2021
27/10Exagen Inc. Expands Coverage with Inland Empire Health Plan, Partnering to Provide More..
27/10Exagen Inc. Partners with Inland Empire Health Plan
25/10EXAGEN : Refinances $27.2 Million of Debt
25/10EXAGEN : Announces $27.2 Million Debt Refinancing - Form 8-K
25/10EXAGEN INC. : Entry into a Material Definitive Agreement (form 8-K)
25/10EXAGEN INC : . Announces $27.2 Million Debt Refinancing
25/10Exagen Inc. Announces $27.2 Million Debt Refinancing
21/10EXAGEN : Showcases Eight Scientific Presentations at ACR's Virtual Annual Meeting in Novem..
19/10EXAGEN INC. : Entry into a Material Definitive Agreement (form 8-K)
20/09EXAGEN INC.(NASDAQGM : XGN) added to S&P Global BMI Index
13/09EXAGEN INC : . to Participate in the 2021 Cantor Fitzgerald Virtual Global Healthcare Conf..
27/08EXAGEN INC. : Entry into a Material Definitive Agreement (form 8-K)
10/08EXAGEN : Posts Wider Q2 Loss, Higher Revenue; Company Maintains Full-Year Revenue Outlook
09/08EXAGEN : Management's Discussion and Analysis of Financial Condition and Results of Operat..
09/08EXAGEN : Earnings Flash (XGN) EXAGEN Reports Q2 Loss $-0.38, vs. Street Est of $-0.44
09/08EXAGEN : Earnings Flash (XGN) EXAGEN Posts Q2 Revenue $12.8M, vs. Street Est of $11.4M
09/08EXAGEN INC. : Termination of a Material Definitive Agreement, Results of Operations and Fi..
09/08EXAGEN INC : . Reports Second Quarter 2021 Results
09/08Exagen Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
09/08Exagen Inc. Re-Affirms Revenue Guidance for the Year 2021
30/07EXAGEN : Appoints Ana Hooker to Board of Directors (Form 8-K)
30/07EXAGEN INC. : Change in Directors or Principal Officers (form 8-K)
30/07EXAGEN : Appoints Ana Hooker to Board of Directors
30/07Exagen Inc. Appoints Ana Hooker to Board of Directors
29/07EXAGEN INC : . to Participate in the Canaccord Genuity 41st Annual Growth Conference
26/07EXAGEN : to Announce Second Quarter 2021 Financial Results on August 9, 2021
26/07NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
13/07AVISE® Lupus Test Demonstrates Statistically Significant Clinical Utility in Achieving ..
13/07Exagen Inc. Announces the Publication of Their Latest Clinical Utility Study in Lupus &..
25/06EXAGEN INC.(NASDAQGM : XGN) added to Russell 2000 Value Index
25/06EXAGEN INC.(NASDAQGM : XGN) added to Russell Small Cap Comp Value Index
25/06EXAGEN INC.(NASDAQGM : XGN) added to Russell 2500 Value Index
25/06EXAGEN INC.(NASDAQGM : XGN) added to Russell 3000 Value Index
25/06EXAGEN INC.(NASDAQGM : XGN) added to Russell 3000E Value Index
25/06EXAGEN INC.(NASDAQGM : XGN) added to Russell Microcap Value Index
21/06EXAGEN INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
21/06Certain Restricted Stock Units of Exagen Inc. are subject to a Lock-Up Agreement Ending..
21/06Certain Common Stock of Exagen Inc. are subject to a Lock-Up Agreement Ending on 21-JUN..
21/06Certain Warrants of Exagen Inc. are subject to a Lock-Up Agreement Ending on 21-JUN-202..
21/06Certain Stock Options of Exagen Inc. are subject to a Lock-Up Agreement Ending on 21-JU..
18/06Exagen Elects Frank Stokes to Board of Directors
18/06Exagen Elects Frank Stokes to Board of Directors
24/05Exagen Inc. to Participate in the William Blair 41st Annual Growth Stock Conference
11/05EXAGEN : Management's Discussion and Analysis of Financial Condition and Results of Operat..
11/05EXAGEN : Q1 Net Loss Widens, Reaffirms Full-Year Revenue Guidance
11/05EXAGEN : Earnings Flash (XGN) EXAGEN Posts Q1 Revenue $10.6M, vs. Street Est of $10.5M
11/05EXAGEN : Earnings Flash (XGN) EXAGEN Reports Q1 Loss $-0.48, vs. Street Est of $-0.48
11/05EXAGEN INC. : Results of Operations and Financial Condition (form 8-K)
11/05Exagen Inc. Reports First Quarter 2021 Results
11/05Exagen Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended..
11/05Exagen Inc. Provides Earnings Guidance for the Fiscal Year 2021
11/05QUARTERLY RECORDS : AVISE® CTD Volumes, Ordering Healthcare Providers and Adopters (Form 8..
04/05EXAGEN INC : ., Allegheny Health Network Research Institute and AHN Autoimmunity Institute..
04/05Exagen Inc., Allegheny Health Network Research Institute and Ahn Autoimmunity Institute..
03/05Exagen Announces New Campaign and Initiatives for Lupus Awareness Month
27/04Exagen to Announce First Quarter 2021 Financial Results on May 11, 2021
29/03EXAGEN : to Study Long-Term Effects of COVID-19 in Autoimmune Diseases Development
29/03EXAGEN INC : . Announces Study on the Long-Term Effects of COVID-19 Infection in the Devel..
29/03Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Devel..
29/03Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Devel..
25/03Exagen Inc. Announces Closing of Public Offering of Common Stock, Including Full Exerci..
23/03EXAGEN INC. : Other Events (form 8-K)
23/03EXAGEN : Prices Common Stock Offering at $16.25 Per Share
23/03Exagen Inc. Announces Pricing of Public Offering of Common Stock
1  2  3  4Siguiente
Próximo evento sobre EXAGEN INC.